• Login
  • |
  • Register

CHA™ Expands Consulting Services into Next-Generation Sequencing and Genomics

Cambridge Healthtech Associates™ Expands Consulting Services into Next-Generation Sequencing and Genomics 

Bio-IT World founding editor, Kevin Davies PhD, named strategic advisor to new consulting division 

NEEDHAM, Massachusetts – March 26, 2012 – Cambridge Healthtech Associates™ (CHA™)  announces a new program of consulting and allied services dedicated to the next-generation sequencing and genomics field. 

The expansion of CHA’s consulting group builds on existing expertise in the area of drug safety. The company’s drug safety consulting services are under the direction of Ernest Bush PhD, the firm’s Vice President of Collaborative Projects.  Drug safety clients include the top tier of pharmaceutical and biotech companies, along with numerous technology providers. 

In genomics and next-generation sequencing, CHA has built a successful online community, NGS Leaders™, which focuses on the challenges in these areas. The community currently includes over 4,000 members across industry and academia, including basic research and clinical medicine. 

Spearheading the launch of the new NGS consulting team is Kevin Davies PhD, founding editor of Bio-IT World, and author of the 2010 book The $1,000 Genome. He is also the founding editor of Nature Genetics, the leading peer-review journal in the field of molecular genetics. 

“I am excited to assist the CHA team in bringing their consulting acumen to the burgeoning field of next-gen sequencing,” said Kevin Davies.  “There have been few more disruptive technologies in the past two decades than next-gen sequencing, which is transforming basic, translational and clinical research. This creates immense challenges for new start-ups, medical centers and diagnostics companies. I believe we have the technical, social and market research know-how to help organizations chart a successful course through these rapidly changing conditions.”  

“The success of our NGS Leaders community identified a need for strategic consulting in the industry,”  said Dawn Van Dam, General Manager of Cambridge Healthtech Associates, “I am thrilled that Kevin Davies will be lending his considerable talents to the CHA team. His extensive experience of over twenty years in science publishing and research, as well as his knowledge in genomics and personalized medicine, will be immensely valuable in helping clients with strategic planning, product development and market research.” 

Kevin Davies was born in London and educated at the Universities of Oxford and London. He conducted postdoctoral research at MIT and Harvard Medical School before joining the editorial staff of Nature magazine. During his 20+ years in science publishing and administration, he has authored three books chronicling the medical and societal impact of genomics research: Breakthrough, Cracking the Genome, and The $1,000 Genome. Davies is a regular contributor to the NGS Leaders community.

Cambridge Healthtech Associates™ (CHA™) uses its unique collaborative model to improve the speed, economics and effectiveness of life science research and development, leveraging its consulting, technology evaluations and communities to help clients in the industry achieve their individual goals. Read more at 


Cambridge Healthtech AssociatesContact: Alison Serrano
Email: aserrano@chacoporate.com
Tel: +1 781 972 5482



I-Study: Genomic Interpretation - Who Will Pay?
During this webinar, members of the study review team present preliminary findings of the I-Study, conducted at the Harvard Medical School's 2011 Personalized Medicine Conference.
Twitter Feed

Privacy Policy|Terms of Use